A Label-Free Method to Quantify Early Stage Amyloid Aggregation via Intrinsic Phenylalanine Fluorescence

Abstract The aggregation of amyloid-forming peptides is a dynamic, complex process that underlies their diverse biological activities, from physiological functions to disease-associated dysfunctions. While the structure of fibrillar end-products is well-characterized for most amyloids, the heterogeneous and often transient oligomers, likely key in cytotoxicity, remain poorly investigated, especially for peptides with low-yield aromatic residues. Here, by exploiting and developing flow induced dispersion analysis in both peak and front modes, we demonstrate that intrinsic phenylalanine fluorescence can be harnessed to quantify the conversion of diffusing monomers into nondiffusing oligomers and fibrils. This approach is validated using PSMα3, a tryptophan- and tyrosine-free peptide from S. aureus, known for its fast amyloid fibrillation and key roles in bacterial virulence. We indeed characterize its low-molecular-weight oligomers, and size evolution from 2 to 10 nm over time. Importantly, to further validate the robustness of our front-mode approach, we apply it to hIAPP, a tyrosine-containing, tryptophan-free peptide, with critical outcome in type 2 diabetes. Our results overcome the limitations of traditional biochemical and biophysical amyloid assays by extending analysis from large oligomers and fibrils to small heterogeneous oligomers, under near-physiological conditions. This study thus offers a new analytical framework, thereby filling a critical gap in amyloid research, to probe the early stages of aggregation, key in the design of alternative therapeutics for amyloid-diseases.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2026-11-17
DOI
https://doi.org/10.1021/acsomega.6c11590
Citations
1
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
1.22

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Label-Free Method to Quantify Early Stage Amyloid Aggregation via Intrinsic Phenylalanine Fluorescence

Yacine Amarouchène, Marion Mathelié‐Guinlet, Lucie Khemtémourian, Thomas Salez et al.
1 citations
ACS Omega
Alzheimer's disease research and treatments
1.22
article

A Label-Free Method to Quantify Early Stage Amyloid Aggregation via Intrinsic Phenylalanine Fluorescence

Yacine Amarouchène, Marion Mathelié‐Guinlet, Lucie Khemtémourian, Thomas Salez, Gaëlle Audéoud, Laura Bonnecaze, Louis Moine, Maxime Lavaud
article en
1 citations

Abstract

Abstract The aggregation of amyloid-forming peptides is a dynamic, complex process that underlies their diverse biological activities, from physiological functions to disease-associated dysfunctions. While the structure of fibrillar end-products is well-characterized for most amyloids, the heterogeneous and often transient oligomers, likely key in cytotoxicity, remain poorly investigated, especially for peptides with low-yield aromatic residues. Here, by exploiting and developing flow induced dispersion analysis in both peak and front modes, we demonstrate that intrinsic phenylalanine fluorescence can be harnessed to quantify the conversion of diffusing monomers into nondiffusing oligomers and fibrils. This approach is validated using PSMα3, a tryptophan- and tyrosine-free peptide from S. aureus, known for its fast amyloid fibrillation and key roles in bacterial virulence. We indeed characterize its low-molecular-weight oligomers, and size evolution from 2 to 10 nm over time. Importantly, to further validate the robustness of our front-mode approach, we apply it to hIAPP, a tyrosine-containing, tryptophan-free peptide, with critical outcome in type 2 diabetes. Our results overcome the limitations of traditional biochemical and biophysical amyloid assays by extending analysis from large oligomers and fibrils to small heterogeneous oligomers, under near-physiological conditions. This study thus offers a new analytical framework, thereby filling a critical gap in amyloid research, to probe the early stages of aggregation, key in the design of alternative therapeutics for amyloid-diseases.

ACS Omega
Centre National de la Recherche Scientifique (FR), University of Vienna (AT), Université de Bordeaux (FR), Chimie et Biologie des Membranes et des Nanoobjects (FR), Laboratoire Ondes et Matière d'Aquitaine (FR), Institut Polytechnique de Bordeaux (FR)
European Commission, Centre National de la Recherche Scientifique, Hokkaido University, Université de Bordeaux, HORIZON EUROPE European Research Council
Openalex Percentile: Top 29%
Alzheimer's disease research and treatments
1.22
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon